Posted Sep. 23, 2010 at 10:30 a.m.
Icagen
Pfizer to pay Icagen $5M to continue drug research
Post a comment
Print this blog postE-mail blog post
Share
Icagen
RESEARCH TRIANGLE PARK, N.C. – Icagen (Nasdaq: ICGND) is getting a $5 million boost from drug giant Pfizer to continue joint research into potential drugs for pain relief and other disorders.
Icagen, which recently executed a reverse stock split, has worked with Pfizer over the past three years.
Pfizer is funding research with a $5 million commitment through December 2011.
If development milestones are met, Icagen would receive some $359 million.
Get the latest news alerts: Follow LTW at Twitter.
Please log in to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
Best of TechWire Insider
OUR INSIDERS
WRAL TechWire Editor
The Skinny
NC Biotech Center braces for worst as Senate slashes budget, too- ArchiveSocial, a new Durham success story, brings home international award
- Durham's high-tech infrastructure, talent lure Virginia company
- Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy
- Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows